Surgery Partners (SGRY) Fundamental Analysis: Revenue, Earnings & Valuation

7.42 / 10

Outperform

Fundamental analysis rates SGRY as Outperform with a 7.4/10 rating. Profit‑MV and Cash‑MV are strong, while Net‑profit/Total‑profit and Revenue‑MV lag. ROA, asset quality and cash flow ratios support a promising outlook despite revenue concerns.

Analysis Checks(8/10)

Revenue-MV

Value1.25

Score1/3

Weight-8.65%

1M Return-0.97%

ROA (%)

Value1.24

Score2/3

Weight6.27%

1M Return0.64%

Net cash flow from operating activities / Operating revenue (%)

Value8.29

Score2/3

Weight14.89%

1M Return1.48%

Profit-MV

Value0.77

Score2/3

Weight32.15%

1M Return3.09%

Annualized net profit margin on total assets (%)

Value1.24

Score2/3

Weight6.27%

1M Return0.64%

EBIT / Total operating revenue (%)

Value11.77

Score3/3

Weight16.01%

1M Return1.53%

Asset-MV

Value-0.55

Score2/3

Weight5.50%

1M Return0.57%

Net profit / Total operating revenue (%)

Value2.99

Score3/3

Weight14.31%

1M Return1.41%

Cash-MV

Value0.56

Score3/3

Weight32.07%

1M Return2.92%

Net profit / Total profit (%)

Value84.60

Score1/3

Weight-18.82%

1M Return-2.39%

Is SGRY fundamentally strong?

SGRY scores 7.42/10 on fundamentals and holds a Discounted valuation at present. Backed by its -2.18% ROE, 2.99% net margin, -20.24 P/E ratio, 0.45 P/B ratio, and 54.14% earnings growth, these metrics solidify its Outperform investment rating.